Twitter Beğeni Hilesi

Congratulations to Payal Kapur Genentech Dinesh Rakheja KidneyCancerProgram and all on jci.me/176743/pdf reporting mechanism of transformation of #chRCC #sarcomatoid

3 renal cancer biomarker orals #ASC024 (Len/pem v sun, axi/pem v sun, atezo v placebo). DNA,RNA, protein & blood(KIM1) data. Below is a summary of progress to date. Will this change or is it more exploratory datawith problems>solutions? Do 151RNA signatures have a future #ASCO24

⚡️ On European Urology - Cabozantinib + nivolumab shows promising results in non–clear cell renal cell carcinoma. With a 48% response rate and median overall survival of 28 months, this combination offers a potential new treatment option. No new safety concerns were observed.

#SahilDoshi Martin Voss Memorial Sloan Kettering Cancer Center with nice analysis of chromophobe #kidneycancer — doublets with targeted treatments better than monotherapy. ASCO #ASCO24 KCCure OncoAlert logist

So proud of Soki Kashima ! Amazing job presenting his project on scRNAseq to identify T cell programs associated with response/resistance. Many thanks to Toni Choueiri, MD and all collaborators/team members. #ASCO24 Yale Cancer Center

Hot flashes significantly impact pts on ADT. As led by Bradley Stish in a double blinded, placebo controlled Alliance for Clinical Trials in Oncology study, oxybutynin significantly improves hot flashes a/w ADT (⬇️ #, frequency, & burden). The tx was well tolerated. Good news for pts w/ prostate cancer! #ASCO24

Beautiful synthesis of complex studies assessing genomic biomarkers across CLEAR (Toni Choueiri, MD), KN426 (Brian Rini, MD) & 010 (Laurence Albiges). Main takeaway: Need prospective validation of KIM1! #ASCO24

What a tour de force on variant/non-clear cell/rare variant RCC by the inimitable Sumanta K. Pal, MD, FASCO! Covering a lot of ground from current therapeutic strategies to ongoing trials and even nomenclature. Some progress has been made but still a long way to go. ASCO #ASCO24

Huge congrats to #NizarTannirMD MD Anderson Cancer Center who drove forward this impt trial (#PIVOT09) comparing pegylated #IL2/#nivolumab to #TKI; was a privelege to work w him & others (Maria Nirvana Formiga, MD, PhD Neeraj Agarwal, MD, FASCO Dan George) on this trial now in Journal of Clinical Oncology. PFS & OS no different;

See 👇: Epigenomic subtyping of sarcomatoid RCC in tissue and liquid biopsies. Potential implications for diagnosis, monitoring, and tx selection in sRCC! Congrats to Talal El Zarif, MD Karl Semaan, MD, MSc Sylvan Baca MD PhD (Hiring!) Toni Choueiri, MD #MattFreedman

Unsolved problems and unmet needs in non clear cell renal carcinoma by Gabriel Malouf #CARARE #JOUM24 Association Française d'Urologie - AFU

Today is #WorldKidneyCancerDay! This year's theme emphasizes the importance of listening to kidney cancer patients and caregivers. "We need to listen" empowers patients by ensuring their voices are heard and valued in their treatment journey. Stay tuned for more!

Événement - Journée Mondiale du Cancer du Rein C'est aujourd'hui ! Cette année, nous explorons le pouvoir de l’écoute. ➡️ Plus d'informations sur notre site : artur-rein.org/actus-artur/pa…

Updated National Comprehensive Cancer Network (NCCN) guidelines (1.2025) are in, with some major changes for systemic therapies: 1) Ipi+Nivo is now a preferred regimen in fav-risk ccRCC 2) Len+Pem/Cabo+Nivo are now preferred regimens for non-clear cell RCC 3) Adjuvant Pembro is now Category 1 KidneyCAN

1/5 Excited to share our @MsaouelLab clinical analysis of 135 patients with #RenalMedullaryCarcinoma treated MD Anderson Cancer Center over 20 years 👉sciencedirect.com/science/articl… #endRMC #rarecancers Kidney Cancer Chris Johnson Foundation Inc. RMC Alliance R.M.C. Inc Rare Cancer Research Foundation + Pattern.org The Renal Medullary Carcinoma Research Foundation KCCure

Kimryn Rathmell Dr. Kimryn Rathmell Sumanta K. Pal, MD, FASCO Katie Coleman Salvatore La Rosa Aly-Khan Lalani Christopher Wallis (he/him/his) Dr. Bishoy M. Faltas Tian Zhang, MD, MHS Samson W. Fine, MD 3/5 Heading steadily towards our benchmark goals to improve median survival to 2 years by 2025 & to 5 years by 2030: aacrjournals.org/cancerres/arti… Avoiding treatments made for clear cell #kidneycancer & introducing biology-driven salvage therapies such as EGFRi made a difference.

Full article here: doi.org/10.1016/j.clgc… #cancerresearch #genitourinary #renalcarcinoma

1/Out today @nature, a paper from Divya Bezwada and DeBerardinis Lab Children’s Research Institute at UT Southwestern about metabolism in human clear cell renal cell carcinoma (ccRCC). Divya identified an unexpected metabolic change that allows these tumors to metastasize. 🧵below.-RJD nature.com/articles/s4158…

Our study on sex differences in Xp11 translocation renal cell carcinoma is out Cell! We ascribe a genetic basis to the female bias in tRCC, which is driven by a translocation of the TFE3 gene on the X chromosome. w Zhang lab @danafarbernews bit.ly/4dtpNtP 🧵1/

As we observe #ChildhoodCancerAwarenessMonth, let’s honor the children we’ve lost and recognize the bravery and resilience of those facing cancer. Join me in our fight against childhood cancer and supporting these courageous children and families. #CCAM #ChildhoodCancer